Prognostic Impact of the Immune-Cell Infiltrate in N1-Positive Non-Small-Cell Lung Cancer.

Autor: Eichhorn F; Department of Thoracic Surgery, Thoraxklinik, Heidelberg University, Heidelberg, Germany; Translational Lung Research Center, German Center for Lung Research (DZL), Heidelberg, Germany. Electronic address: florian.eichhorn@med.uni-heidelberg.de., Weigert A; Institute of Biochemistry I, Faculty of Medicine, Goethe-University Frankfurt, Frankfurt, Germany; Frankfurt Cancer Institute (FCI), Goethe University, and German Cancer Consortium (DKTK), Partner Site Frankfurt, Frankfurt, Germany., Nandigama R; Institute for Lung Health (ILH), Justus Liebig University, Giessen, Germany; Max Planck Institute for Heart and Lung Research, Member of the German Center for Lung Research (DZL), Member of the Cardio-Pulmonary Institute (CPI), Bad Nauheim, Germany., Klotz LV; Department of Thoracic Surgery, Thoraxklinik, Heidelberg University, Heidelberg, Germany; Translational Lung Research Center, German Center for Lung Research (DZL), Heidelberg, Germany., Wilhelm J; Institute for Lung Health (ILH), Justus Liebig University, Giessen, Germany; Internal Medicine, University of Giessen and Marburg Lung Center, Member of the German Center for Lung Research, Giessen, Germany., Kriegsmann M; Translational Lung Research Center, German Center for Lung Research (DZL), Heidelberg, Germany; Institute of Pathology Wiesbaden, Wiesbaden, Germany., Allgäuer M; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany., Muley T; Translational Lung Research Center, German Center for Lung Research (DZL), Heidelberg, Germany; Section Translational Research (STF), Thoraxklinik, Heidelberg University, Heidelberg, Germany., Christopoulos P; Translational Lung Research Center, German Center for Lung Research (DZL), Heidelberg, Germany; Department of Thoracic Oncology, Thoraxklinik, Heidelberg University Hospital, Heidelberg, Germany., Savai R; Frankfurt Cancer Institute (FCI), Goethe University, and German Cancer Consortium (DKTK), Partner Site Frankfurt, Frankfurt, Germany; Institute for Lung Health (ILH), Justus Liebig University, Giessen, Germany; Max Planck Institute for Heart and Lung Research, Member of the German Center for Lung Research (DZL), Member of the Cardio-Pulmonary Institute (CPI), Bad Nauheim, Germany., Eichhorn ME; Department of Thoracic Surgery, Thoraxklinik, Heidelberg University, Heidelberg, Germany; Translational Lung Research Center, German Center for Lung Research (DZL), Heidelberg, Germany., Winter H; Department of Thoracic Surgery, Thoraxklinik, Heidelberg University, Heidelberg, Germany; Translational Lung Research Center, German Center for Lung Research (DZL), Heidelberg, Germany.
Jazyk: angličtina
Zdroj: Clinical lung cancer [Clin Lung Cancer] 2023 Dec; Vol. 24 (8), pp. 706-716.e1. Date of Electronic Publication: 2023 Jun 28.
DOI: 10.1016/j.cllc.2023.06.013
Abstrakt: Introduction: The tumoral immune milieu plays a crucial role for the development of non-small-cell lung cancer (NSCLC) and may influence individual prognosis. We analyzed the predictive role of immune cell infiltrates after curative lung cancer surgery.
Materials and Methods: The tumoral immune-cell infiltrate from 174 patients with pN1 NSCLC and adjuvant chemotherapy was characterized using immunofluorescence staining. The density and distribution of specific immune cells in tumor center (TU), invasive front (IF) and normal tissue (NORM) were correlated with clinical parameters and survival data.
Results: Tumor specific survival (TSS) of all patients was 69.9% at 5 years. The density of tumor infiltrating lymphocytes (TIL) was higher in TU and IF than in NORM. High TIL density in TU (low vs. high: 62.0% vs. 86.7%; p = .011) and the presence of cytotoxic T-Lymphocytes (CTLs) in TU and IF were associated with improved TSS (positive vs. negative: 90.6% vs. 64.7% p = .024). High TIL-density correlated with programmed death-ligand 1 expression levels ≥50% (p < .001). Multivariate analysis identified accumulation of TIL (p = .016) and low Treg density (p = .003) in TU as negative prognostic predictors in squamous cell carcinoma (p = .025), whereas M1-like tumor- associated macrophages (p = .019) and high programmed death-ligand 1 status (p = .038) were associated with better survival in adenocarcinoma.
Conclusion: The assessment of specific intratumoral immune cells may serve as a prognostic predictor in pN1 NSCLC. However differences were observed related to adenocarcinoma or squamous cell carcinoma histology. Prospective assessment of the immune-cell infiltrate and further clarification of its prognostic relevance could assist patient selection for upcoming perioperative immunotherapies.
Competing Interests: Disclosure Thomas Muley has received grants/contracts from Roche Diagnostics and Oncohost outside the submitted work. Petros Christopoulos has received research funding from AstraZeneca, Amgen, Boehringer Ingelheim, Novartis, Roche, and Takeda, speaker's honoraria from AstraZeneca, Janssen, Novartis, Roche, Pfizer, Thermo Fisher, Takeda, support for attending meetings from AstraZeneca, Eli Lilly, Daiichi Sankyo, Gilead, Novartis, Pfizer, Takeda, and personal fees for participating to advisory boards from Boehringer Ingelheim, Chugai, Pfizer, Novartis, MSD, Takeda and Roche, all outside the submitted work. Hauke Winter has received received payment (lectures, presentations, speaker fee, manuscript writing, educational events) from MSD, AstraZeneca, Intuitive, Medtronic, Roche; expert testimony from Intuitive; support for attending meetings/travel from Roche, Intuitive, MSD and participation on Data Safety Monitoring/Advisory Board for AstraZeneca and Intuitive; all outside the submitted work. Florian Eichhorn, Andreas Weigert, Rajender Nandigama, Laura Klotz, Jochen Wilhelm, Mark Kriegsmann, Michael Allgäuer, Rajkumar Savai and Martin Eichhorn declare that they have no known conflict of interest or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2023 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE